Amgen's fundamentals stay strong with rising EPS, dividend yield, and new drug momentum, despite technical pullbacks. See why ...

Amgen’s adjusted earnings per share reached $4.90, exceeding expectations and marking a 24% increase year-over-year. Total ...

Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook ...

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...

Fuller & Thaler Asset Management upped its Amgen stake by 12.9% in Q4, signaling continued faith in the biotech juggernaut. The firm now holds 36,971 shares valued at $9.64 million, a clear vote of ...

Amgen (AMGN) came out with quarterly earnings of $4.90 per share, beating the Zacks Consensus Estimate of $4.16 per share. This compares to earnings of $3.96 per share a year ago. These figures are ...

Reliable dividend income from high-quality companies is a great option for investors seeking to ride out stock market ...

Burling Wealth Partners LLC added 929 shares of Amgen to its portfolio in Q4, worth about $242,000—a modest but calculated ...

Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Kyprolis ...

LONDON (Reuters) -The chief executive of generic drugmaker Sandoz (SIX: SDZ) said a proposal by the CEOs of Novartis (SIX: NOVN) and Sanofi (NASDAQ: SNY) to introduce a Europe-wide list price for new ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of ...